Drug General Information
Drug ID	D08NAD
Former ID	DIB012320
Drug Name	Batabulin
Synonyms	T-138067; T-138068; T-67
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 2/3	[521550]
Company	Tularik Inc
Structure		Download 2D MOL 3D MOL
Formula	C13H6F6NNaO3S
Canonical SMILES	S(=O)(=O)(c1c(c(c(c(c1F)F)F)F)F)Nc1cc(c(cc1)OC)F
CAS Number	CAS 195533-53-0
PubChem Compound ID	23669770
Target and Pathway
Target(s)	Tubulin beta	Target Info	Inhibitor	[526170]
KEGG Pathway	Phagosome
	Gap junction
	Pathogenic Escherichia coli infection
NetPath Pathway	FSH Signaling Pathway
	TCR Signaling Pathway
	EGFR1 Signaling Pathway
PANTHER Pathway	Cytoskeletal regulation by Rho GTPase
	Huntington disease
Reactome	Regulation of PLK1 Activity at G2/M Transition
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
WikiPathways	Parkin-Ubiquitin Proteasomal System pathway
	Pathogenic Escherichia coli infection
	Mitotic G2-G2/M phases
References
Ref 521550	ClinicalTrials.gov (NCT00057382) T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients. U.S. National Institutes of Health.
Ref 526170	Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.